EPI-001
EPI-001 is a novel experimental non-steroidal antiandrogen that is under investigation for the treatment of prostate cancer. The drug is being developed by the pharmaceutical company ESSA Pharma Inc (Vancouver, Canada) for the treatment of castration-resistant prostate cancer (CRPC) and is currently in pre-clinical development. As of 2016, EPI-001's successor, EPI-506, is under clinical investigation in a phase I/II study.
Wikipage redirect
primaryTopic
EPI-001
EPI-001 is a novel experimental non-steroidal antiandrogen that is under investigation for the treatment of prostate cancer. The drug is being developed by the pharmaceutical company ESSA Pharma Inc (Vancouver, Canada) for the treatment of castration-resistant prostate cancer (CRPC) and is currently in pre-clinical development. As of 2016, EPI-001's successor, EPI-506, is under clinical investigation in a phase I/II study.
has abstract
EPI-001 is a novel experimenta ...... igation in a phase I/II study.
@en
IUPAC name
3-(4-{2-[4-(3-Chloro-2-hydroxypropoxy)phenyl]-2-propanyl}phenoxy)-1,2-propanediol
@en
PubChem
thumbnail
Wikipage page ID
38,508,096
Wikipage revision ID
730,165,150
ChemSpiderID
legal status
Investigational
molecular weight
smiles
StdInChIKey
HDTYUHNZRYZEEB-UHFFFAOYSA-N
subject
hypernym
comment
EPI-001 is a novel experimenta ...... igation in a phase I/II study.
@en
label
EPI-001
@en
